Skip to main contentSkip to navigation
Sirius Investors
Avecho Biotechnology Limited

Avecho Biotechnology Limited

AVEFF
OTCHealthcare

Avecho Biotechnology Limited (AVEFF) Investment Research Dashboard

About Avecho Biotechnology Limited (AVEFF) stock analysis

Get live AVEFF stock price $0.00, comprehensive Avecho Biotechnology Limited stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time AVEFF stock data and investment insights.

0.00
20.00%Today
Market Cap
13.91M
Volume
300.00K
52W High
0.00
52W Low
0.00

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Avecho Biotechnology Limited is an Australian-based firm specializing in the development, production, and sale of various products. Central to its operations is the proprietary and patented Targeted Penetration Matrix (TPM) drug delivery system, whic...

Company Information

CEO
Paul Gavin
Sector
Healthcare
Industry
Biotechnology
Employees
15

Contact Information

Address
2A Westall Road
Country
AU

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Avecho Biotechnology Limited shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Avecho Biotechnology Limited
  • Investors should consider how Avecho Biotechnology Limited fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

13.91M

P/E Ratio (TTM)

-14.40

Beta

1.13

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

69/100 ⭐⭐⭐⭐

Overall
+0.5%
NYSE
+0.6%
NASDAQ
+0.5%
Sector1D1W1MP/EScore
Financial Services+1.6%+2.6%+3.7%19.2
98/100⭐⭐⭐⭐⭐
Consumer Defensive+1.4%+3.5%+2.4%30.2
78/100⭐⭐⭐⭐⭐
Healthcare+0.5%+1.1%+1.4%24.0
69/100⭐⭐⭐⭐
Communication Services+0.6%-1.4%+2.2%22.0
67/100⭐⭐⭐⭐
Basic Materials+0.7%+1.5%+0.0%25.2
66/100⭐⭐⭐⭐
Real Estate+0.2%+0.7%-1.8%29.4
50/100⭐⭐⭐
Energy-0.5%-2.2%-2.6%19.4
41/100⭐⭐⭐
Utilities-0.8%+0.2%-4.2%26.9
36/100⭐⭐
Consumer Cyclical+0.2%-1.8%-6.1%42.6
18/100
Industrials-0.4%-0.6%-10.8%29.8
18/100
Technology-0.7%-2.9%-8.3%40.1
8/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.